Stop vaccinations immediately!

https://www.medias-presse.info/57-personnalites-scientifiques-et-medicales-internationales-expliquent-pourquoi-il-faut-larret-immediat-de-toutes-les-vaccinations-anti-covid/142464/

57 leading scientists and doctors explain why all COVID vaccinations must be stopped immediately

France Soir reveals that a group of 57 leading scientists, doctors and political experts published a report questioning the safety and effectiveness of the current COVID-19 “vaccines” and calling for an immediate end to all vaccination programs.

The therapies used as "vaccines" do not match the definition of the word vaccine and would more appropriately be referred to as gene therapies or vaccine vector therapies.

 

There are two certainties about the worldwide prevalence of these Covid-19 therapies:

• The first is that governments and the vast majority of the mainstream media are making every effort to get these experimental drugs out to as many people as possible.
• The second is that those who are willing to face the scorn that comes with asking serious questions about vaccines are essential players in our ongoing efforts to spread the truth.

This manuscript can be read in the pre-print below. It was prepared by nearly sixty doctors, scientists and public order experts from around the world and should be urgently addressed to world leaders, as well as to everyone involved in the production and distribution of the various Covid-19 vaccines in circulation. be transmitted.

 

In addition, there are still a number of unanswered questions about the safety, effectiveness and necessity of these Covid-19 therapies.

 

This study is a bang and should be read by anyone, regardless of their views on gene therapy or vaccines. Not enough citizens are asking critical questions about this. Most people simply obey the orders of their governments as if they deserve their full trust. However, this is not the case. This manuscript is a step forward in accountability and the free flow of information on this important topic. Please take the time to read and spread the word.

 

Mass Vaccination Against SARS-CoV-2:
Urgent Vaccine Safety Questions That Need To Be Answered By International Health Authorities, Regulators, Governments, And Vaccine Developers

 

Authors: Roxana Bruno (1), Peter McCullough (2), Teresa Forcades i Vila (3), Alexandra Henrion-Caude (4), Teresa García-Gasca (5), Galina P. Zaitzeva (6), Sally Priester (7 ), María J. Martínez Albarracín (8), Alejandro Sousa-Escandon (9), Fernando López Mirones (10), Bartomeu Payeras Cifre (11), Almudena Zaragoza Velilla (10), Leopoldo M. Borini () 1, Mario Mas (1), Ramiro Salazar (1), Edgardo Schinder (1), Eduardo A Yahbes (1), Marcela Witt (1), Mariana Salmeron (1), Patricia Fernández (1), Miriam M. Marchesini (1), Alberto J. Kajihara (1), Marisol V. de la Riva (1), Patricia J. Chimeno (1), Paola A. Grellet (1), Matelda Lisdero (1), Pamela Mas (1), Abelardo J. Gatica Baudo (12), Elisabeth Retamoza (12), Oscar Botta (13), Chinda C. Brandolino (13), Javier Sciuto (14), Mario Cabrera Avivar (14),Mauricio Castillo (15), Patricio Villarroel (15), Emilia P. Poblete Rojas (15), Bárbara Aguayo (15), Dan I. Macías Flores (15), Jose V. Rossell (16), Julio C. Sarmiento (17 ), Victor Andrade-Sotomayor (17), Wilfredo R. Stokes Baltazar (18), Virna Cedeño Escobar (19), Ulises Arrúa (20), Atilio Farina del Río (21), Tatiana Campos Esquivel (22), Patricia Callisperis ( 23), María Eugenia Barrientos (24), Karina Acevedo-WhitehouseKarina Acevedo-WhitehouseKarina Acevedo-Whitehouse

 

Preface

 

Since the beginning of the COVID-19 epidemic, an unprecedented race to test new platforms designed to confer immunity against SARS-CoV-2 has broken out, leading to the emergency approval of various vaccines. Despite advances in early multidrug-resistant therapy for COVID-19 patients, the current mission is to vaccinate the world's population as soon as possible. The lack of extensive animal testing prior to clinical trials and approval based on safety data obtained in studies lasting less than 3.5 months raises questions about the safety of these vaccines. The recently identified role of the SARS-CoV-2 spike glycoprotein in inducing the endothelial damage characteristic of COVID-19, even in the absence of infection, is highly relevant as most approved vaccines induce the production of spike glycoproteins in recipients. Given the high rate of adverse event occurrences and the wide range of types of adverse events reported to date, as well as the potential for vaccine-induced disease aggravation, Th2 immunopathology, autoimmunity and immune evasion, there is a need for a better understanding of the benefits and risks of mass vaccination, in particular in groups excluded from clinical trials. Despite calls for caution, the risks of vaccination against SARS-CoV-2 have been downplayed or ignored by health organizations and government agencies.

 

introduction

 

Since the Covid-19 pandemic was proclaimed in March 2020, more than 150 million cases and 3 million deaths have been reported worldwide. Despite the advances in early outpatient multi-drug resistant therapy for high-risk patients, which has led to an 85 percent reduction in Covid-19-related hospital stays and deaths [1], the current control paradigm is mass vaccination. While we acknowledge the effort involved in developing, manufacturing, and emergency licensing SARS-CoV-2 vaccines, we are concerned that the risks have been minimized or ignored by health organizations and government agencies, despite caution [2– 8th].

 

Vaccines against other coronaviruses have never been approved for humans, and the data gained in the development of coronavirus vaccines that are designed to elicit neutralizing antibodies show that they can treat COVID-19 disease through antibody-dependent enhancement (ADE ) and Th2 immunopathology can worsen regardless of vaccine. Platform and delivery method [9–11]. It is known that in animals vaccinated against SARS-CoV and MERS-CoV, after a viral challenge, an exacerbation of the disease occurs, which is attributed to immune complexes and the Fc-mediated uptake of the virus by macrophages that cause the T  Increase cell activation and inflammation [11  13].

 

In March 2020, vaccine immunologists and coronavirus experts assessed the risks of the SARS-CoV-2 vaccine based on SARS-CoV vaccine trials in animal models. The panel concluded that undesirable side effects and immunopathology were a real problem, but stated that their risk was insufficient to delay clinical trials, although continuous monitoring would be required [14]. Although there is no clear evidence of the occurrence of ADRs and vaccine-related immunopathology in test subjects who were immunized with SARS-CoV-2 vaccines [15], these serious adverse events (SAEs) have not been specifically investigated in previous safety studies. Given the fact Since the follow-up of the subjects did not last longer than 2–3.5 months after the second dose [16–19], it is unlikely that such an SAE was observed. Despite 92 reporting errors, it cannot be overlooked that even taking into account the number of vaccines administered, according to the US Vaccine Adverse Event Reporting System (VAERS), the number of deaths per million vaccine doses administered has increased more than ten-fold. We believe that there is an urgent need for an open scientific dialogue on vaccine safety in the context of large-scale vaccination. that even considering the number of vaccines administered, according to the US Vaccine Adverse Event Reporting System (VAERS), the number of deaths per million vaccine doses administered has increased more than ten-fold. We believe that there is an urgent need for an open scientific dialogue on vaccine safety in the context of large-scale vaccination. that even considering the number of vaccines administered, according to the US Vaccine Adverse Event Reporting System (VAERS), the number of deaths per million vaccine doses administered has increased more than ten-fold. We believe that there is an urgent need for an open scientific dialogue on vaccine safety in the context of large-scale vaccination.

 

In this article, we describe some of the risks of mass vaccination related to exclusion criteria for Phase 3 trials and discuss the GSSs reported in national and regional adverse event registration systems. We point out unanswered questions and draw attention to the need for a more cautious approach to mass vaccination. We believe that there is an urgent need for an open scientific dialogue on vaccine safety in the context of large-scale vaccination.

 

Exclusion criteria for the phase 3 study SARS-CoV-2

 

With a few exceptions, the SARS-CoV-2 vaccine studies have excluded the elderly [16–19], making it impossible to identify post-vaccination post-vaccination post-vaccination post-vaccination post-vaccination inflammation in the elderly of eosinophilia and increased inflammation, the occurrence of eosinophilia and increased inflammation in the elderly have been excluded. Studies with SARS-CoV vaccines have shown that immunized older mice have a particularly high risk of potentially fatal Th2 immunopathology [9,20]. Despite these findings and the extremely limited data on the safety and effectiveness of SARS-CoV-2 vaccines in the elderly, mass vaccination campaigns have focused on this age group from the start. Most studies also included pregnant and breastfeeding subjects, as well as people with chronic and serious illnesses such as tuberculosis, hepatitis C, autoimmunity, coagulopathies,

 

Another exclusion criterion in almost all studies was previous exposure to SARS-CoV-2. This is unfortunate because it has eliminated the possibility of obtaining highly relevant information about post-vaccination adverse events in people who already have anti-SARS-Cov-2 antibodies. To the best of our knowledge, ADEs are not routinely monitored for any age or disease group currently receiving the vaccine. In addition, although a significant portion of the population already has antibodies [21], testing for anti-SARS-CoV-2 antibody status prior to vaccine administration is not routinely performed.

 

Do Serious Adverse Events With SARS-CoV-2 Vaccines Go Undetected?

 

COVID-19 covers a broad clinical spectrum, ranging from very mild to severe pulmonary pathology to fatal multi-organ diseases with inflammatory, cardiovascular and / or blood clotting dysregulations [22–24]. In this sense, vaccine-related ADR or immunopathology could not be clinically differentiated from severe COVID-19 [25]. In addition, the spike glycoprotein alone, even in the absence of the SARS-CoV-2 virus, causes endothelial damage and high blood pressure in Syrian hamsters in vitro and in vivo by downregulating the angiotensin-converting enzyme 2 (ACE2) and changing mitochondrial function [ 26]. Although these results have yet to be confirmed in humans, the implications of this finding are staggering, as all vaccines approved for emergency use are based on the administration or induction of spike glycoprotein synthesis. In the case of mRNA and adenovirus vaccines, the duration of spike production in humans after vaccination has not been investigated in any study.

 

It should be borne in mind that vaccine-induced spike synthesis may cause clinical signs of severe COVID-19 infection and could be mistakenly counted as new cases of SARS-CoV-2 infection. If so, the real negative effects of the current global vaccination strategy may never be realized unless studies specifically investigate this issue. There is already non-causal evidence of a temporary or sustained increase in deaths from COVID-19 after vaccination in some countries (Fig. 1). Given the spike pathogenicity, these deaths must be carefully investigated to determine if they are vaccine-related. No studies have looked at the duration of spike production in humans after vaccination.

 

Unexpected adverse reactions to SARS-CoV-2 vaccines

 

Autoimmunity is another critical issue to consider given the global scale of SARS-CoV-2 vaccination. SARS-CoV   2 has many immunogenic proteins, and all but one have similarities to human proteins [27]. These can serve as a source of antigens, which leads to autoimmunity [28]. While it is true that the same effects could be observed with a natural infection with SARS-CoV-2, the vaccination is intended for the majority of the world's population, while it is estimated that only 10% of the world's population are infected with SARS-CoV-2, according to this Dr. Michael Ryan, director of the World Health Organization's emergency department. We couldn't find any evidence

 

Some adverse events, including bleeding disorders, have been reported in healthy young vaccinees. These cases have resulted in the suspension or discontinuation of the use of ChAdOx1-nCov-19 and adenoviral vectorized vaccines by Janssen in some countries. It has now been suggested that vaccination with ChAdOx1-nCov-19 can lead to immune thrombotic thrombocytopenia (ITT), which is mediated by platelet-activating antibodies against platelet factor   4 and clinically mimics heparin-induced autoimmune thrombocytopenia [29]. Unfortunately, the risk was overlooked in approving these vaccines, although adenovirus-induced thrombocytopenia has been known for more than a decade and is a consistent event with adenoviral vectors [30]. The risk of TTIV is likely to be higher in people who are already at risk for blood clots.

 

Vaccine-related effects can also occur at the population level. SARS-CoV   2 is a rapidly developing RNA virus that has so far produced more than 40,000 variants [32,33], some of which affect the antigenic domain of the spike glycoprotein [34,35]. In view of the high mutation rates, the vaccine-induced synthesis of high levels of anti-SARS-CoV-2 spike antibodies in vaccinated people could theoretically lead to suboptimal reactions to subsequent infections with other variants [36], a phenomenon known as "Sin" [37 ] or antigenic priming [38] is known. The extent to which mutations affecting the antigenicity of SARS-CoV-2 are fixed during viral evolution is unknown [39], but it is conceivable that vaccines may act as selective forces, which lead to variants with higher infectivity or transmissibility. Given the high similarity between the known SARS-CoV-2 variants, this scenario is unlikely [32,34], but if future variants should differ further in key epitopes, the global vaccination strategy may have helped shape an even more dangerous virus. The WHO was recently made aware of this risk in the form of an open letter [40]. to shape an even more dangerous virus. The WHO was recently made aware of this risk in the form of an open letter [40]. to shape an even more dangerous virus. The WHO was recently made aware of this risk in the form of an open letter [40].

 

discussion

 

The risks described here represent a major obstacle to the continuation of the global vaccination against SARS-CoV-2. The safety of all SARS-CoV-2 vaccines must be proven before more people are exposed to the risk of these experiments than the release of one Vaccine candidates without time to fully understand the resulting health implications could exacerbate the current global crisis. [41]. Risk stratification of the vaccinated is essential. According to the UK government, people under the age of 60 have an extremely low risk of dying from COVID-19. However, according to Eudravigillance, most serious adverse events after SARS-CoV-2 vaccination occur in people aged 18–64 years. Of particular concern is the planned vaccination schedule for children 6 years and older in the US and UK. Dr. Anthony Fauci recently forecast that teenagers across the country will be vaccinated in the fall and younger children in the spring of 2022. Lee UK is waiting for study results to begin vaccinating 11 million children under the age of 18 with the experimental vaccines as they have a 99.997% survival rate when infected with SARS-CoV   2, according to the Centers for Disease Control and Prevention are. Not only is COVID-19 irrelevant as a threat to this age group, there is also no reliable evidence which demonstrate the effectiveness or effectiveness of the vaccine in this population group or exclude harmful side effects of these experimental vaccines. With this in mind, as doctors advise patients to administer COVID-19 electively, there is a great need to better understand the benefits and risks of administration, especially in studied groups.

 

In summary, in connection with the emergency approval of the use of SARS-CoV-2 vaccines and the current gaps in our understanding of their safety, the following questions must be asked:
- Is it known whether cross-reacting antibodies from previous coronavirus infections or vaccine-induced antibodies can influence the risk of unintended pathogenesis after vaccination with COVID-19?

• Has the specific risk of adverse effects, immunopathology, autoimmunity and serious adverse reactions been clearly communicated to vaccine recipients to meet the medical ethical standard of patient understanding for informed consent? If not, what are the reasons and how could it be implemented?
• What is the reason to give the vaccine to each individual if the risk of dying from COVID-19 is not the same across all age groups and clinical conditions, and if the phase 3 studies are elderly, children and frequent specific Excluded conditions?
• What rights do patients have if they are harmed by a SARS-CoV-2 vaccine? Who pays for medical treatment? If claims were to be settled with public money, has the public been informed that immunity has been granted to vaccine manufacturers and that their responsibility to compensate vaccine victims has been transferred to taxpayers?

Against the background of these concerns, we propose to stop mass vaccination and to open an urgent, pluralistic, critical and scientifically based dialogue on vaccination against SARS-CoV-2 between scientists, doctors, international health agencies, regulators, governments and vaccine developers. This is the only way to bridge the current gap between scientific knowledge and public health policy regarding SARS-CoV-2 vaccines. We believe that humanity deserves a deeper understanding of the risks than what is currently presented as an official position. An open scientific dialogue is urgently needed to avoid the erosion of public trust in science and public health; and to ensure that WHO and national health authorities protect the interests of humanity during the current pandemic. There is an urgent need to move public health policy back towards evidence-based medicine, based on a careful assessment of relevant scientific research. It is imperative to follow science. return public health policy to evidence-based medicine based on careful assessment of relevant scientific research. It is imperative to follow science. return public health policy to evidence-based medicine based on careful assessment of relevant scientific research. It is imperative to follow science.

 

1 www.gov.uk/government/publications/covid-19-reported-sars-cov-2-deaths-in-england/covid-19-confirmed-deaths-in-england-report

 

Conflict of Interest Statement

 

The authors state that the research was conducted in the absence of any commercial or financial relationship that could be construed as a potential conflict of interest.

 

credentials

1. McCullough PA, Alexander PE, Armstrong R, et al. Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV   2 infection (COVID-19). Rev Cardiovasc Med (2020) 21: 517-530. doi: 10.31083 / j.rcm.2020.04.264
2. Arvin AM, Fink K, Schmid MA, et al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature (2020) 484: 353-363. doi: 10.1038 / s41586-020 2538 8
3. Coish JM, MacNeil AJ. Out of the frying pan and into the fire? Due diligence warranted for ADE in COVID-19. Microbes Infect (2020) 22 (9): 405-406. doi: 10.1016 / j.micinf.2020.06.006
4. Eroshenko N, Gill T, Keaveney ML, et al. Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures. Nature Biotechnol (2020) 38: 788-797. doi: 10.1038 / s41587-020-0577-1
5. Poland GA. Tortoises, hares, and vaccines: A cautionary note for SARS-CoV-2 vaccine development. Vaccine (2020) 38: 4219-4220. doi: 10.1016 / j.vaccine.2020.04.073
6. Shibo J. Don't rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees. Nature (2000) 579,321. doi: 10.1038 / d41586-020–00751 9
7. Munoz FA, Cramer JP, Dekker CL, et al. Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine (2021)  doi.org/10.1016/j.vaccine.2021.01.055
8. Cardozo T, Veazey R. Informed consent disclosure to vaccine trial subjects of risk of COVID-19 vaccines worsening clinical disease. Int J Clin Pract (2020) 28: e13795. doi: 10.1111 / ijcp.13795
9. Bolles D, Long K, Adnihothram S, et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol (2001) 85: 12201-12215. doi: 10.1128 / JVI.06048-11
10. Weingartl H, Czub M, Czub S, et al. Immunization with modified vaccinia virus Ankarabased recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol (2004) 78: 12672-12676. doi: 10.1128 / JVI.78.22.12672-12676.2004272
11. Tseng CT, Sbrana E, Iwata-Yoshikawa N, et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One (2012) 7 (4): e35421. doi: 10.1371 / journal.pone.0035421
12. Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in COVID-19. Nat Rev Immunol (2020) 20: 339-341. doi: 10.1038 / s41577-020-0321-6
13. Vennema H, de Groot RJ, Harbor DA, et al. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. J Virol (1990) 64: 1407-1409
14. Lambert PH, Ambrosino DM, Andersen SR, et al. Consensus summary report for CEPI / BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines. Vaccine (2020) 38 (31): 4783-4791. doi: 10.1016 / j.vaccine.2020.05.064
15. de Alwis R, Chen S, Gan S, et al. Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development. EbioMedicine (2020) 55: 102768. doi: 10.1016 / j.ebiom.2020.102768
16. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV? 287 19 vaccine against SARS-CoV   2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet (2020) 396: 467-783. doi: 10.1016 / S0140-6736 (20) 31604-4
17. Polack FP, Thomas SJ, Kitchin N. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med (2020) 383: 2603-2615. doi: 10.1056 / NEJMoa2034577
18. Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomized, controlled, phase 2/3 trial. Lancet (2021) 396: 1979-93. doi: 10.1016 / S0140-6736 (20) 32466-1
19. Chu L, McPhee R, Huang W, et al. mRNA-1273 Study Group. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV   2 vaccine. Vaccine (2021) S0264-410X (21) 00153-5. doi: 10.1016 / j.vaccine.2021.02.007
20. Liu L, Wei Q, Lin Q, et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight (2019) 4 (4): e123158. doi: 10.1172 / jci.insight.123158.
21. Ioannidis PA. Infection fatality rate of COVID-19 inferred from seroprevalence data. Bull WHO (2021) 99: 19-33F. dx.doi.org/10.2471/BLT.20.265892
22. Martines RB, Ritter JM, Matkovic E, et al. Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus Disease, United States Emerg Infect Dis (2020) 26: 2005-2015. doi: 10.3201 / eid2609.202095
23. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA (2020) 323: 1239-1242. doi: 10.1001 / jama.2020.2648
24. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respiratory Med (2020) 8: 420-422 doi: 10.1016 / S2213-2600 (20) 30076-X
25. Negro F. Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis? Swiss Medical Weekly (2020) 150: w20249. doi: 10.4414 / smw.2020.20249317
26. Lei Y, Zhang J, Schiavon CR et al., Spike Protein Impairs Endothelial Function via Downregulation of ACE 2. Circulation Res (2021) 128: 1323-1326. doi.org/10.1161/CIRCRESAHA.121.318902
27. Lyons-Weiler J. Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity, J Translational Autoimmunity (2020) 3: 100051. doi: 10.1016 / j.jtauto.2020.100051
28. An H, Park J. Molecular Mimicry Map (3M) of SARS-CoV   2: Prediction of potentially immunopathogenic SARS-CoV   2 epitopes via a novel immunoinformatic approach. bioRxiv [preprint]. 12 November 2020 [cited 2020 April 19]  doi.org/10.1101/2020.11.12.344424
29. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med (2021). doi: 10.1056 / NEJMoa2104840
30. Othman M, Labelle A, Mazzetti I, et al. Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. Blood (2007) 109: 2832-2839. doi: 10.1182 / blood-2006-06-032524
31. Ortel TL. Acquired thrombotic risk factors in the critical care setting. Crit Care Med (2010) 38 (2 Suppl): S43-50. doi: 10.1097 / CCM.0b013e3181c9ccc8
32. Grubaugh ND, Petrone ME, Holmes EC. We shouldn't worry when a virus mutates during disease outbreaks. Nat Microbiol (2020) 5: 529-530. doi.org/10.1038/s41564-020-0690-4
33. Greaney AJ, Starr TN, Gilchuk P, et al. Complete Mapping of Mutations to the SARS-CoV? 339 2 Spike Receptor-Binding Domain that Escape Antibody Recognition. Cell Host Microbe (2021) 29: 44-57.e9. doi: 10.1016 / j.chom.2020.11.007.
34. Lauring AS, Hodcroft EB. Genetic Variants of SARS-CoV-2 — What Do They Mean? JAMA (2021) 325: 529-531. doi: 10.1001 / jama.2020.27124
35. Zhang L, Jackson CB, Mou H, et al. The D614G mutation in the SARS-CoV   2 spike protein reduces S1 shedding and increases infectivity. bioRxiv [preprint]. June 12 2020 [cited 2021 Apr 19]  doi.org/10.1101/2020.06.12.148726
36. Korber B, Fischer WM, Gnanakaran S et al. Sheffield COVID-19 Genomics Group. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell (2020) 182: 812-827.e19. doi: 10.1016 / j.cell.2020.06.043
37. Francis T. On the doctrine of original antigenic sin. Proc Am Philos Soc (1960) 104: 572-578.
38. Vibroud C, Epstein SL. First flu is forever. Science (2016) 354: 706-707. doi: 10.1126 / science.aak9816
39. Weisblum Y, Schmidt F, Zhang F, et al. Escape from neutralizing antibodies by SARS? 354 CoV-2 spike protein variants. Elife (2020) 9: e61312. doi: 10.7554 / eLife.61312
40. Vanden Bossche G (March 6, 2021)  dryburgh.com/wp-356content/uploads/2021/03/Geert_Vanden_Bossche_Open_Letter_WHO_March_6_2021.pdf
41. Coish JM, MacNeil AJ. Out of the frying pan and into the fire? Due diligence warranted for ADE in COVID-19. Microbes Infect (2020) 22 (9): 405-406. doi: 10.1016 / j.micinf.2020.06.006

 

Captions

 

Figure 1: Number of new deaths from COVID-19 versus number of people who received at least one vaccine dose for selected countries. The graph shows data from the start of vaccination through May 3, 365, 2021. A) India (9.25% of the vaccinated population), B) Thailand (1.58% of the vaccinated population), C) Colombia (6.79 % of the vaccinated population), D) Mongolia (31.65% of the vaccinated population), E) Israel (62.47% of the vaccinated population), F) worldwide (7.81% of the vaccinated population). The charts were created using data from Our World in Data (accessed May 4, 2021) at github.com/owid/covid–19–données/arbre/maître/public/données/vaccinations

 

Affiliations *

 

  1. Epidemiólogos Argentinos Metadisciplinarios. República Argentina.
  2. Baylor University Medical Center. Dallas, Texas, USA.
  3. Monestir de Sant Benet de Montserrat, Montserrat, Spain
  4. INSERM U781 Hôpital Necker-Enfants Malades, Université Paris Descartes-Sorbonne Cité,

      Institut Imagine, Paris, France.
  5. Science School. Autonomous University of Querétaro, Querétaro, Mexico.
  6. Retired Professor of Medical Immunology. Universidad de Guadalajara, Jalisco, Mexico.
  7. Médicos por la Verdad Puerto Rico. Ashford Medical Center. San Juan, Puerto Rico.
  8. Retired Professor of Clinical Diagnostic Techniques. University of Murcia, Murcia, Spain
  9. Urologist, Comarcal de Monforte Hospital, University of Santiago de Compostela, Spain.
10. Biólogos por la Verdad, Spain.
11. retired biologist. University of Barcelona. Specialized in microbiology. Barcelona, Spain.
12. Center for Integrative Medicine MICAEL (Medicina Integrativa Centro Antroposófico Educando

       en Libertad). Mendoza, Argentine Republic.
13. Médicos por la Verdad Argentina. República Argentina.
14. Médicos por la Verdad Uruguay. República Oriental del Uruguay.
15. Médicos por la Libertad Chile. Republic of Chile.
16. doctor, orthopedist. Republic of Chile.
17. Médicos por la Verdad Perú. República del Perú.
18. Medicos por la Verdad Guatemala. Republic of Guatemala.
19. Concepto Azul SA Ecuador.
20. Médicos por la Verdad Brasil. Brazil.
21. Médicos por la Verdad Paraguay.
22. Médicos por la Verdad Costa Rica.
23. Médicos por la Verdad Bolivia.
24. Médicos por la Verdad El Salvador.

 

* Correspondence: Karina Acevedo-Whitehouse, karina.acevedo.whitehouse@uaq.mx